DE957596C - Process for the production of antigens from the foot and mouth disease vaccine - Google Patents

Process for the production of antigens from the foot and mouth disease vaccine

Info

Publication number
DE957596C
DE957596C DEW14845A DEW0014845A DE957596C DE 957596 C DE957596 C DE 957596C DE W14845 A DEW14845 A DE W14845A DE W0014845 A DEW0014845 A DE W0014845A DE 957596 C DE957596 C DE 957596C
Authority
DE
Germany
Prior art keywords
production
virus
antigens
foot
mouth disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired
Application number
DEW14845A
Other languages
German (de)
Inventor
Dr Otto Waldmann
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer AG
Siemens Healthcare Diagnostics GmbH Germany
Original Assignee
Behringwerke AG
Bayer AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Behringwerke AG, Bayer AG filed Critical Behringwerke AG
Priority to DEW14845A priority Critical patent/DE957596C/en
Application granted granted Critical
Publication of DE957596C publication Critical patent/DE957596C/en
Expired legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • A61K39/125Picornaviridae, e.g. calicivirus
    • A61K39/135Foot- and mouth-disease virus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/55Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
    • A61K2039/552Veterinary vaccine
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/32011Picornaviridae
    • C12N2770/32111Aphthovirus, e.g. footandmouth disease virus
    • C12N2770/32134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Virology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Zoology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Feed For Specific Animals (AREA)

Description

Verfahren zur Gewinnung von Antigenen der Maul-und Klauenseuche -Vaccine Zur Gewinnung des Antigens für die Produktion der Vaccine gegen Maul- und Klauenseuche folgt man zur Zeit den Vorschriften der Entdecker der Vaccine Waldmann und Köbe. Die Methode ist veröffentlicht in der Berliner tierärztlichen Wochenschrift I938, Nr. 22, S. 3I7, und im Centralblaft für Bakteriologie 148, S. iff (1941)..Process for the production of antigens of the foot and mouth disease -Vaccine To the Extraction of the antigen for the production of the vaccine against foot and mouth disease the rules of the discoverers of the vaccines Waldmann and Köbe are currently being followed. The method is published in the Berlin veterinary weekly I938, No. 22, p. 3I7, and in the Centralblaft für Bakteriologie 148, p. Iff (1941) ..

Das Antigen wird bislang in der Weise gewannen, daß erwachsene Rinder von 300 bis 400 kg Gewicht mit dem MKS-Erreger auf der Zunge infiziert werden. Die Tiere erkranken innerhalb 24 Stunden, es entstehen Blasen an den Impfstellen der Zungen. Nach 24 Stunden werden die Tiere getötet und die Blasen abgenommen. Der Inhalt dieser Blasen (Lymphe) und die Aphthendecken sind das virushaltige Rohmaterial, das. nach geeigneter Zubereitung als Antigen für die Vaccine dient. The antigen has so far been obtained in the manner that adult cattle 300 to 400 kg in weight are infected with the foot-and-mouth pathogen on the tongue. the Animals fall ill within 24 hours, blisters appear at the vaccination sites Tongues. After 24 hours, the animals are sacrificed and the bladders are removed. Of the The content of these blisters (lymph) and the aphthous cover are the raw material containing the virus, that. Serves as an antigen for the vaccine after suitable preparation.

Dieses Verfahren der Antigengewinnung ist schwierig und. kostspielig. Die Rinder müssen hochempfänglich, d. h. ohne jede Immunität sein und sind schwer zu kaufen, wenn die Seuche schon einen großen Teil des Landes. ergriffen hat Die künstliche Infektion dieser Tiere, die Schlachtung und die Gewinnung der spezifischen Lessionen muß wegen der Gefahr der Verschleppung der Seuche unter strengster Isolierung stattfinden; dazu sind teure bauliche Investierungen nötig. Die Verwertung des Fleisches zwingt ebenfalls zu besonderen Maßnahmen. This method of obtaining antigen is difficult and. expensive. The cattle must be highly receptive, i. H. be without any immunity and are difficult to buy when the plague has been a large part of the country. has seized the artificial infection of these animals, the slaughter and the extraction of the specific Lessionen must be kept under strict isolation because of the risk of spreading the epidemic occur; expensive structural investments are necessary for this. The utilization of the meat also forces special measures.

Wir konnten feststellen; daß es bei neugeborenen, spontan empfänglichen Kälbern. nach pareNteraler Infektion mit MKS-Virus zu einer Erkrankung mit außerordentlicher Entwicklung des Virus in den verschiedensten Organen kommt. Die Extrakte aus diesen Organen sind noch in einer Verdünnung von I zu 100 000 infektiös, in Mengen von 0,20cm injiziert. Diese Beobachtung bildet die Grundlage des Verfahrens. der vorliegenden. Erfindung zur Herstellung von Antigenen der MKS-Vaccine, welches darin besteht, daß Kälber bald nach der Geburt mit MKS-Virus. infiziert, nach erfolgter Generaksation des Virus getötet und aus den virushaltigen Organen, insbesondere aus dem Knochenmark, das Antigen in an sich. bekannter Weise ge wonnen wird. We could determine; that in newborns it is spontaneously receptive Calves. after parenteral infection with foot-and-mouth disease virus to a disease with extraordinary The virus develops in various organs. The extracts from these Organs are still infectious in a dilution of 1 in 100,000, in amounts of 0.20cm injected. This observation forms the basis of the procedure. the present. Invention for the production of antigens of the FMD vaccine, which consists in that calves with foot-and-mouth disease virus soon after birth. infected after generation of the virus and from the organs containing the virus, in particular from the bone marrow, the antigen in itself. known way ge is obtained.

Der Vorteil dieses Verfahrens ergibt sich aus folgender Gegenüberstellung: Ein erwachsenes Rind liefert im Durchschnitt 35 g Rohmaterial. Die für dieVaccinedosis benötigteGenviclhtsmenge Rohmaterial (Antigen) beträgt 0,1 g, so daß aus der Ernte eines infizierten, erwachsenen Rinder 350 Dosen monovalenter Vaccine hergestellt werden können. The advantage of this procedure results from the following comparison: An adult cattle provides an average of 35 g of raw material. The one for the vaccine dose Required amount of raw material (antigen) is 0.1 g, so that from the harvest of an infected adult cattle produced 350 doses of monovalent vaccine can be.

Zur Herstellung von frivalenter Vaccine wird die dreifache Menge Antigen gebraucht. Three times the amount is required to produce frival vaccine Antigen needed.

Das. erfindungsgemäße Verfahren der Gewinnung des. Antigens vom Kalb gibt folgendes Bild: Das Virus vermehrt sich nach künstlicher Infektion außerordentlich rasch in Form einer Sepsis und führt nach spätestens 48 Stunden zum Tode. Die einzelnen Organe enthalten das Virus in versebiedener Konzentration. Am stärksten und regelmäßigsten findet sich das. Virus im Knochenmark, in der Lunge und im Herzen. That. Process according to the invention for obtaining the antigen from calf gives the following picture: The virus multiplies extraordinarily after an artificial infection rapidly in the form of sepsis and leads to death after 48 hours at the latest. The single ones Organs contain the virus in varying concentrations. Strongest and most regular the virus is found in the bone marrow, lungs and heart.

Diese Organe, die alle einzeln auf ihren Virusgehalt getestet werden, werden erfindungsgemäß als Rohmaterial für die Vaccineherstellung benutzt. These organs, which are all individually tested for their virus content, are used according to the invention as a raw material for vaccine production.

Auf diese Weise können aus einem Kalb mehr als 3 kg Rohmaberial gewonnen werden..In this way, more than 3 kg of raw material can be obtained from one calf will..

Somit werden zur Herstellung von 3 kg Rohmaterial vom erwachsenen Rind 100 Rinder be nötigt, während erfindungsgemäß dieselbe Menge von einem Kalb erzielt wird. Das Verfahren der Rohstoffgewinnung wird stark vereinfacht und die Gefahr der Verschleppung der Seuche von den Gewinnungsstellen aus praktisch unmöglich gemacht. Thus, for the production of 3 kg of raw material from the adult Beef 100 cattle be required, while according to the invention the same amount of one calf is achieved. The process of raw material extraction is greatly simplified and the The risk of spreading the disease from the extraction points is practically impossible made.

Es war bekannt, bei der Vaccinegewiinnung an Stelle von ausgewachsenen Rindern von Jungtieren auszugehen. It was known to be used in vaccine production in lieu of adult To assume cattle from young animals.

Gegenstand der Erfindung ist demgegenüber die Verwendung neugeborener, höchstens 1 Tag alter Kälber, welche vor der Aufnahme der Kolostralmilch mit Virus infiziert werden. Dies ist deshalb von Wichtigkeit, weil die Kolostralmilch beim Rind, ebenso wie beim Menschen, Ubefträgerin spezifischer und unspezifischer Abwehrstoffe gegen Infektionen. ist. Der Krankheitsverlauf bei neugeborenen Kälbern, die noch keine Kolostralmilch bekommen haben, ist ein septischer und führt nach etwa 4c Stunden zum Tode-. Kälber, die Kolostralmilch bekommen haben, reagieren ganz anders; sie erkranken erst nach langer Inkubationszeit und dann, ähnlich wie beim erwachsenen Rind, in der exanthematischen Form. In contrast, the subject of the invention is the use of newborn, no more than 1-day-old calves which have been infected with the virus before the colostrum get infected. This is important because the colostrum when Cattle, as well as humans, carry specific and unspecific antibodies against infections. is. The course of the disease in newborn calves that are still If you have not received any colostrum, this is a septic result and takes about 4c hours to death-. Calves given colostrum react very differently; she become ill only after a long incubation period and then, similar to the adult Beef, in the exanthematic form.

Claims (2)

PATENTANsPRÜcHE: I. Verfahren zur Herstellung von Antigenen der MKS-Vaccine, dadurch gekennzeichnet, daß Kälber bald nach der Gebaut und vor Aufnahme der Kolostralmilch mit MKS-Virus infiziert, nach erfolgter Generalisation des Virus getötet und aus den virushaltigen Organen das Antigen in an sich bekannter Weise gewonnen wird. PATENT CLAIMS: I. Process for the production of antigens of the FMD vaccine, characterized in that calves are built soon after and before the colostrum is consumed infected with FMD virus, killed after generalization of the virus and removed the virus-containing organs, the antigen is obtained in a manner known per se. 2. Verfahren gemäß Anspruch I, dadurch ge; kennzeichnet, daß die Antigene aus dem Knochenmark gewonnen werden. 2. The method according to claim I, characterized ge; indicates that the Antigens are obtained from the bone marrow. In Betracht gezogene Druckschriften: Deutsche Patentschriften Nr. 279213, 279 693, 598 573, 653 680. Publications considered: German Patent Specifications No. 279213, 279 693, 598 573, 653 680.
DEW14845A 1954-09-10 1954-09-10 Process for the production of antigens from the foot and mouth disease vaccine Expired DE957596C (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
DEW14845A DE957596C (en) 1954-09-10 1954-09-10 Process for the production of antigens from the foot and mouth disease vaccine

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DEW14845A DE957596C (en) 1954-09-10 1954-09-10 Process for the production of antigens from the foot and mouth disease vaccine

Publications (1)

Publication Number Publication Date
DE957596C true DE957596C (en) 1957-02-07

Family

ID=7595375

Family Applications (1)

Application Number Title Priority Date Filing Date
DEW14845A Expired DE957596C (en) 1954-09-10 1954-09-10 Process for the production of antigens from the foot and mouth disease vaccine

Country Status (1)

Country Link
DE (1) DE957596C (en)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE279213C (en) *
DE279693C (en) *
DE598573C (en) * 1932-12-07 1934-06-13 Claus Schilling Dr Process for the preparation of a vaccine for newborn animals for vaccination against trypanosomal diseases

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE279213C (en) *
DE279693C (en) *
DE598573C (en) * 1932-12-07 1934-06-13 Claus Schilling Dr Process for the preparation of a vaccine for newborn animals for vaccination against trypanosomal diseases
DE653680C (en) * 1932-12-07 1937-11-30 Dr Claus Schilling Process for the preparation of a vaccine for newborn animals to be vaccinated against trypanosomes

Similar Documents

Publication Publication Date Title
DE2717919A1 (en) PROCESS FOR MANUFACTURING A HORSE RHINOPNEUMONIC VACCINE AND VACCINE MANUFACTURED BY THIS PROCESS
DE2817299A1 (en) METHOD OF PRODUCING ATTENUATED INFECTIOUS GASTROENTERITIS (TGE) VIRUS STRAIN FOR USE IN LIVE VACCINES
DE1957747A1 (en) Vaccines and processes for their manufacture
DE957596C (en) Process for the production of antigens from the foot and mouth disease vaccine
DE2803240B2 (en) Rabies virus, method of making a live ToUwut vaccine or inactivated vaccine and its use in combating rabies
DE2632255A1 (en) NEW RABIES VIRUS VACCINE AND METHOD FOR PRODUCING IT
Cunningham Immunization of cattle against Theileria parva
EP0564620B1 (en) Dermatomycosis vaccine
DE2538994A1 (en) BACTERIAL VACCINE AND METHOD FOR MANUFACTURING IT
DE1492243C3 (en) Injectable vaccines
DE2421084A1 (en) Compsns. contg. Bifidobacterium longum - for animal, esp. pig, rearing and therapy
DE68927380T2 (en) VACCINE
DE2805311A1 (en) RESPIRATORY SYNCYTIAL VACZINE
DE1692043C3 (en) Rhinopneumonitis vaccines and processes for their manufacture
DE1235505B (en) Process for the production of a vaccine against distemper
DE69208854T2 (en) Vaccine preparation for preventing miscarriage in animals caused by Chlamydia psitacci
AT234902B (en) Process for the production of a vaccine against distemper
CH634993A5 (en) Process for the preparation of an agent for the prophylaxis and therapy of gastroenteritis
DE1021128B (en) Process for the manufacture of a vaccine against rhinotracheitis in cattle
DEW0014845MA (en)
DE936890C (en) Process for the preparation of live foot-and-mouth disease virus vaccines
DE2162013C3 (en) Live rabies vaccine, process for its preparation and use in the control of rabies
AT226368B (en) Process for the production of a vaccine
DE814315C (en) Process for the production of serums, vaccines and the like like
DE1041214B (en) Process for the manufacture of vaccines against viral diseases